Engineered bearings and power transmission products manufacturer and distributor Solve Industrial Motion Group has acquired D&D Global — a conveyor bearings manufacturer headquartered in Rock Valley, ...

It’s officially a deal spree for Solve Industrial Motion. The engineered bearings and power transmission products distributor announced Oct. 27 the acquisition of Miller Bearing Company — a conveyor ...

A century-old North Atlantic cold patch is now linked to a long-term slowdown in the AMOC, the climate-regulating conveyor belt of ocean water. Only weakened-AMOC models match observed temperature and ...

Solve Intelligence, the AI platform for the $200B+ patent industry, has raised $40M in Series B funding and is launching a new product for generating patent claim charts. Solve’s Series B comes just ...

The new round, which follows a $12 million Series A earlier this year, includes participation from Thomson Reuters and the founder of Quinn Emanuel’s IP litigation practice. Solve Intelligence ...

Editor's Note: This article mentions sexual assault. Months after the University established the Presidential Task Force on Campus Sexual Assault early last Spring, no updates have been released to ...

Funding round was led by Yosemite, with participation from new investors Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, and all existing investors SAN ...

SAN DIEGO--(BUSINESS WIRE)--Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumor malignancies, today announced it has ...

A San Diego biotech has set out to solve the formula for best-in-class antibody-drug conjugates, raising $120 million with support from Big Pharma Merck & Co. to fuel its efforts. Solve Therapeutics’ ...

Funding round was led by Yosemite, with participation from new investors Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, and all existing investors Solve ...

The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of the issues limiting the potential of earlier ADCs. Many of these newer ...

Solve Therapeutics, a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for solid tumor malignancies, has raised $120 million in an oversubscribed and upsized financing ...